Literature DB >> 18373958

2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling.

Stevan P Tofovic1, Xinchen Zhang, Hong Zhu, Edwin K Jackson, Olga Rafikova, Gordana Petrusevska.   

Abstract

Our previous studies show that 2-methoxyestradiol, a non-estrogenic metabolite of estradiol (E2), attenuates the development and retards the progression of pulmonary hypertension (PH) in male rats, and in female rats prevents the exacerbation of PH and eliminates mortality due to ovariectomy. Recent studies suggest that 2-ethoxyestradiol (2-EE), a synthetic analog of 2-ME, is an even more potent antimitogen than 2-ME. The goals of this study were: 1) to compare the effects of E2, 2-ME and 2-EE on proliferation of human pulmonary artery endothelial (hPAEC) and smooth muscle cells (hPASMC) and lung fibroblasts (hLF); 2) to examine the effects of 2-ME, its metabolic precursor 2-hydroxyestradiol (2-HE) and 2-EE on isoproterenol (ISO)-induced cardiac hypertrophy in male rats; and 3) to investigate in male rats the effects of 2-EE (10 mug/kg/h via osmotic pump) on the development of monocrotaline (MCT; 60 mg/kg i.p.)-induced PH. E2 had biphasic effects on growth (stimulation at low and inhibition at high concentrations) in hPAEC and mild growth inhibitory effects in hPASMC and hLF (1-10 muM). In contrast, in all three pulmonary cell lines, 2-ME and 2-EE inhibited cell growth with 2-EE being ten times more potent than 2-ME. In ISO-induced cardiac hypertrophy, 2-ME, 2-HE and 2-EE similarly reduced (~-50%) left (LV) and right (RV) ventricular hypertrophy and fibrosis (hydroxyproline content). In animals with MCT-induced PH, treatment with 2-EE for 28 days significantly decreased the elevated RV peak systolic pressure and reduced RV/LV+septum weight ratio, strongly inhibited vascular remodeling (media hypertrophy and adventitia widening), markedly reduced inflammatory responses, and eliminated MCT-induced (63%) mortality. This study provides the first evidence that 2-ethoxyestradiol strongly inhibits vascular remodeling in PH and suggests that anti-proliferative agents, including synthetic analogs of estradiol metabolites may be protective in PH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18373958     DOI: 10.1016/j.vph.2008.02.001

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  14 in total

Review 1.  Pulmonary hypertension in women.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-11

Review 2.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

Review 3.  Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Womens Health (Lond)       Date:  2010-03

Review 4.  Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease.

Authors:  Stevan P Tofovic
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

Review 5.  Novel approaches to treat experimental pulmonary arterial hypertension: a review.

Authors:  S Umar; P Steendijk; D L Ypey; D E Atsma; E E van der Wall; M J Schalij; A van der Laarse
Journal:  J Biomed Biotechnol       Date:  2010-03-22

6.  Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females.

Authors:  E D Austin; J D Cogan; J D West; L K Hedges; R Hamid; E P Dawson; L A Wheeler; F F Parl; J E Loyd; J A Phillips
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

Review 7.  Estrogen paradox in pulmonary hypertension: current controversies and future perspectives.

Authors:  Soban Umar; Marlene Rabinovitch; Mansoureh Eghbali
Journal:  Am J Respir Crit Care Med       Date:  2012-05-03       Impact factor: 21.405

8.  2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats.

Authors:  Stevan P Tofovic; Xinchen Zhang; Edwin K Jackson; Hong Zhu; Gordana Petrusevska
Journal:  Vascul Pharmacol       Date:  2009-06-21       Impact factor: 5.773

Review 9.  Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response.

Authors:  K M Mair; A K Z Johansen; A F Wright; E Wallace; M R MacLean
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 10.  Treatment of pediatric pulmonary hypertension.

Authors:  Amy Hawkins; Robert Tulloh
Journal:  Vasc Health Risk Manag       Date:  2009-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.